Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Benitec Biopharma Inc.NASDAQ: BNTC
Net Income · Q3 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $11.94M (cash outflow) rose 27.6% year over year, behind the +56.8% change in trailing-twelve-month net income. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +27.7% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$47.19M (+24.5%) for the fiscal year ending Jun 2026, a slowdown from the +74.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$11.94M+0.8% QoQ
- Last fiscal yearJun 2025
- -$37.92M+74.3% YoY
- LTMMar 2026
- -$41.54M+56.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.6% | +48.5% | +20.9 pp |
| 1 year | +74.3% | +24.5% | -49.9 pp |
| 3-year CAGR | +27.7% | +22.8% | -4.9 pp |
| 5-year CAGR | +4.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (37.92M) USD
- Year-over-year change
- -74.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (37.92M) | -74.3% |
| FY2024 | 2024-06-30 | (21.75M) | -11.2% |
| FY2023 | 2023-06-30 | (19.56M) | -7.4% |
| FY2022 | 2022-06-30 | (18.21M) | -31.2% |
| FY2021 | 2021-06-30 | (13.88M) | — |
Net Income vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's LTM Mar 2026 net income of $41.54M is the 8th largest of the 10 companies compared; the peer median is $98.64M.
- Its year-over-year change of +56.8% is the 3rd highest of 10, against a peer median of +22.0%.
- Over three fiscal years its annual growth of +27.7% compares with a peer median of +21.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $288.97M | +21.3% | +24.5% | 312.1% | |
| LTM Mar 2026 | $191.78M | +37.3% | +26.6% | — | |
| FY2025 | $110M | -495.9% | +43.7% | 2360.9% | |
| LTM Mar 2026 | $103.82M | +3.1% | -8.5% | 5605.9% | |
| LTM Mar 2026 | $98.64M | +22.0% | +17.9% | — | |
| LTM Mar 2026 | $71.67M | +24.7% | -7.9% | 1605.2% | |
| LTM Mar 2026 | $64.01M | +294.9% | +34.1% | 433.1% | |
| LTM Mar 2026 | $41.54M | +56.8% | +27.7% | — | |
| LTM Mar 2026 | $26.92M | +1041.4% | — | 74.3% | |
| LTM Mar 2026 | $26.25M | -41.9% | -7.4% | — | |
| Peer median (excluding BNTC) | $98.64M | +22.0% | +21.2% | 1019.2% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| Deferred Income Tax | 0 | 0 | (714K) | 0 | 0 |
| Stock-Based Compensation | 634K | 870K | 452K | 830K | 17.43M |
| Change in Working Capital | 8K | 1.04M | 714K | 1.17M | (2.73M) |
| Accounts Receivables | 28K | 1K | (50K) | (176K) | 197K |
| Inventory | (83K) | (1.09M) | (1.31M) | 0 | 0 |
| Accounts Payables | 55K | 1.09M | 1.36M | 0 | (2.38M) |
| Other Working Capital | 8K | 1.04M | 714K | 1.35M | (548K) |
| Other Non-Cash Items | (16K) | 10K | 717K | 1K | (764K) |
| Operating Cash Flow | (12.83M) | (15.9M) | (18.01M) | (19.4M) | (23.59M) |
| Capital Expenditures | (221K) | (13K) | (1K) | (179K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (221K) | (13K) | (1K) | (179K) | (18K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.75M | 0 | 17.88M | 70.88M | 70.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | 0 | (1.87M) | (2.85M) | 0 |
| Financing Cash Flow | 22.52M | 0 | 16.02M | 68.03M | 70.49M |
| Effect of Forex Changes | 499K | 204K | 412K | (8K) | 49K |
| Net Change in Cash | 9.97M | (15.71M) | (1.59M) | 48.44M | 46.93M |
| Free Cash Flow | (13.05M) | (15.91M) | (18.01M) | (19.58M) | (23.61M) |
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.